SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced positive registrational data from the ARROS-1 trial…

GSK plc · 6-K filed Sep 14, 2026 at 07:04 ET

At the news

BULLISHIMPACT 7/10

6-K filed Sep 14, 2026 at 07:04 ET

GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in first-line ROS1-positive NSCLC, showing a 94% objective response rate and 90% 12-month progression-free survival. The results support a planned supplemental NDA to the FDA in 2026 to expand the indication from second-line to first-line treatment, which could meaningfully expand the drug's addressable market and peak sales potential.

  • 94% objective response rate (ORR) in 94 TKI-naïve patients at 15.2 months median follow-up
  • 90% of patients progression-free at 12 months; median PFS not yet reached
  • 70% of patients with measurable brain metastases achieved complete intracranial clearance
  • Only 1% treatment discontinuation rate due to TRAEs; 11% dose reduction rate

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access